SELECT PUBLICATIONS
Giantonio BJ et al. Impact of bevacizumab dose reduction on clinical outcomes for
patients treated on the Eastern Cooperative Oncology Group’s Study E3200. Proc ASCO
2006;Abstract 3538.
Giantonio BJ et al. High-dose bevacizumab improves survival when combined with
FOLFOX4 in previously treated advanced colorectal cancer: Results from the Eastern
Cooperative Oncology Group (ECOG) study E3200. Proc ASCO 2005;Abstract 2.
Hurwitz H et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med 2004;350(23):2335-42. Abstract
Maindrault-Goebel F et al. OPTIMOX2, a large randomized phase II study of maintenance
therapy or chemotherapy-free intervals (CFI) after FOLFOX in patients with
metastatic colorectal cancer (MRC). A GERCOR study. Proc ASCO 2006;Abstract 3504.
Moroni M et al. Gene copy number for epidermal growth factor receptor (EGFR) and
clinical response to antiEGFR treatment in colorectal cancer: A cohort study. Lancet
Oncol 2005;6(5):279-86. Abstract
Saltz LB et al. Randomized Phase II trial of cetuximab/bevacizumab/irinotecan (CBI)
versus cetuximab/bevacizumab (CB) in irinotecan-refractory colorectal cancer.
Presentation. ASCO 2005;Abstract 3508.
